Home > Interstitial Lung Disease
    Content Type:
  • Interstitial Lung Disease

    An Introduction to Interstitial Lung Disease

    Ongoing translational research is unearthing targetable mechanisms of disease
    progression shared across the spectrum of interstitial lung diseases (ILDs). Recent approvals of antifibrotic therapies slowing loss of lung function have advanced treatment and care options for patients living with progressive ILD. Immunomodulatory agents inhibiting immune-mediated pathways (including interleukin (IL)-6-driven inflammation and adaptive immune cell responses) are currently undergoing
    evaluation for disease modifying properties to preserve lung function in ILD with underlying autoimmune disease.

    Expert video highlights and insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.

    Interstitial Lung Disease Content

    Copied to clipboard!
    accredited arrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greyarrow-right-orangearrow-right-whitearrow-right-blueavatarcalendarchevron-down crosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmenumore_dots padlock person play_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-whiteticktimetranscriptup-arrowwebinar